Actavis plc (NYSE:ACT) confirmed Thursday that it has filed an Abbreviated New Drug Application or ANDA with the U.S. Food and Drug Administration or FDA seeking approval to market Methylphenidate Hydrochloride for Extended-release Oral Suspension, 5 mg/mL. Actavis plc (NYSE:ACT) belongs to Healthcare sector. Its net profit margin is 0.60% and weekly performance is -8.34%. On last trading day company shares ended up $222.07. Actavis … Continue reading Morning Watch List : Actavis plc (NYSE:ACT), Google Inc (NASDAQ:GOOGL), Rouse Properties, Inc. (NYSE:RSE), DCP Midstream Partners LP (NYSE:DPM), Titan Machinery (NASDAQ:TITN)